Short Term Rating on BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) : Zacks Investment Research ranks BioMarin Pharmaceutical (BMRN) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 1.27, which indicates as a Strong Buy.

BioMarin Pharmaceutical (BMRN) : The consensus price target for BioMarin Pharmaceutical (BMRN) is $112.21 for the short term with a standard deviation of $12.46. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $150, however, the pessimist price target for the company is $99.

For the current week, the company shares have a recommendation consensus of Buy.

BioMarin

BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $88.83 on Tuesday but the bulls could not build on the opening and the stock topped out at $89.98 for the day. The stock traded down to $87.43 during the day, due to lack of any buying support eventually closed down at $87.48 with a loss of -1.25% for the day. The stock had closed at $88.59 on the previous day. The total traded volume was 1,725,473 shares.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *